Blood Substitute Approved in S. Africa

Article

JOHANNESBURG, South Africa-A new blood product that has yet to be approved in the US or Europe has been approved in South Africa.

Hemopure is made from cow hemoglobin and is the first human blood substitute. It can be kept for two years at room temperature and has been created from American cows that are seemingly disease-free. Although the manufacturing company, Biopure, says the product can be used as a substitute, doctors say it better to use Hemopure as a bridge until blood supplies are available for transfusion.

Once used, Hemopure loses its effectiveness in a day or two, requiring more transfusions. It also does not give the body platelets and plasma as donated blood does.

Biotechnology companies have been working for two decades to develop an oxygenating product. At least three other companies are in late stages of development of a similar product.

Biopure plans on filing an application for approval of Hemopure in the US and Europe this year. The company has already received approval for a different blood substitute for dogs.

Information from www.arizonarepublic.com

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
In a recent discussion with Infection Control Today® (ICT®), study authors Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio, shared their insights on how the project evolved and what the findings mean for the future.